United Security Bancshares (NASDAQ:UBFO) shares fell -0.57% in last trading session and ended the day at $5.25. UBFO has a return on assets of 1.00%.
Dennis R. Woods, President and Chief Executive Officer of United Security Bancshares (NASDAQ:UBFO), reported that the Board of Directors of United Security Bancshares declared a 4th quarter 2015 stock dividend of one percent (1%) on December 15, 2015. The stock dividend will be paid to shareholders of record on January 4, 2016 and the dividend shares will be issued on January 15, 2016.
Epizyme, Inc. (NASDAQ:EPZM) ended the last trading day at $16.98. Company weekly volatility is calculated as 6.51% and price to cash ratio as 3.08. Epizyme, Inc. (NASDAQ:EPZM) showed a weekly performance of 2.29%.
Epizyme, Inc. (NASDAQ:EPZM), announced the U.S. Food and Drug Administration’s (FDA) Division of Hematology Products has accepted the company’s investigational new drug (IND) application for tazemetostat for the treatment of adults with diffuse large B-cell lymphoma (DLBCL), the most common type of Non-Hodgkin Lymphoma (NHL). An ongoing five-arm registration-supporting, international phase 2 clinical trial assessing the safety and activity of tazemetostat in patients with relapsed or refractory B-cell NHL was initiated in July 2015. The IND acceptance will allow the company to enroll DLBCL patients in the United States into this ongoing trial.
On 28 December, Krispy Kreme Doughnuts, Inc. (NYSE:KKD) shares fell -0.46% and was closed at $15.15. KKD EPS growth in last 5 year was 30.05%. Krispy Kreme Doughnuts, Inc. (NYSE:KKD) year to date (YTD) performance is -23.25%.
Krispy Kreme Doughnuts, Inc. (NYSE: KKD) will be presenting on Wednesday, Jan. 13, 2016 at the 18th Annual ICR Conference at the Grande Lakes Hotel in Orlando, Fla. The presentation is scheduled to begin at 8 a.m. Eastern.
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) shares increased 3.13% in last trading session and ended the day at $22.10. OMED has a return on assets of -34.80%. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) quarterly performance is 50.44%.
Zacks Investment Research upgraded shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) from a sell rating to a hold rating in a research note issued to investors on Friday morning, MarketBeat reports.
PartnerRe Ltd. (NYSE:PRE) caters to the Financial space. It has a net profit margin of 2.60% and weekly performance is 0.63%. On the last day of trading company shares ended up at $139.88. PartnerRe Ltd. (NYSE:PRE) distance from 50-day simple moving average (SMA50) is 0.81%.
On 18 December, PartnerRe Ltd. (NYSE:PRE) announced that subsidiary, Partner Reinsurance Europe SE, was granted a license from the Dubai Financial Services Authority (“DFSA”) to operate as an Authorised Firm in the Dubai International Financial Centre (“DIFC”), effective December 16, 2015.
Leave a Reply